Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol-coated liposome improves antitumor activity in a murine colorectal tumor model

Cancer Science

Volumn 101, Issue 11, 2010, Pages 2470-2475

  Doi, Yusuke ^a   Okada, Tomoko ^a   Matsumoto, Haruna ^a   Ichihara, Masako ^a   Ishida, Tatsuhiro ^a   Kiwada, Hiroshi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 OHP; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; LIPOSOME; MACROGOL; OXALIPLATIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG COATING; DRUG EFFECT; DRUG FORMULATION; DRUG POTENTIATION; DRUG RETENTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG SYNERGISM; HUMANS; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; ORGANOPLATINUM COMPOUNDS; OXONIC ACID; POLYETHYLENE GLYCOLS; TEGAFUR; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 77958568462     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01678.x     Document Type: Article

References (31)

1. Kidani Y, Noji M, Tashiro T. Antitumor activity of platinum(II) complexes of 1, 2-diamino-cyclohexane isomers. Gann 1980; 71: 637-43.
2. Mathe G, Kidani Y, Noji M, Maral R, Bourut C, Chenu E. Antitumor activity of l-OHP in mice. Cancer Lett 1985; 27: 135-43.
3. Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 1993; 53: 5970-6.
4. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-14.
5. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
6. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 6387-92.
7. Suzuki R, Takizawa T, Kuwata Y et al. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. Int J Pharm 2008; 346: 143-50.
8. Abu Lila AS, Kizuki S, Doi Y, Suzuki T, Ishida T, Kiwada H. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model. J Control Release 2009; 137: 8-14.
9. Abu-Lila AS, Suzuki T, Doi Y, Ishida T, Kiwada H. Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model. J Control Release 2009; 134: 18-25.
10. Kano MR, Bae Y, Iwata C et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc Natl Acad Sci USA 2007; 104: 3460-5.
11. Ten Hagen TL, Van Der Veen AH, Nooijen PT, Van Tiel ST, Seynhaeve AL, Eggermont AM. Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats. Int J Cancer 2000; 87: 829-37.
12. Seynhaeve AL, Hoving S, Schipper D et al. Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response. Cancer Res 2007; 67: 9455-62.
13. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4: 423-36.
14. Laquente B, Vinals F, Germa JR. Metronomic chemotherapy: an antiangiogenic scheduling. Clin Transl Oncol 2007; 9: 93-8.
15. Shiraga E, Barichello JM, Ishida T, Kiwada H. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model. Int J Pharm 2008; 353: 65-73.
16. Ishida T, Shiraga E, Kiwada H. Synergistic antitumor activity of metronomic dosing of cyclophosphamide in combination with doxorubicin-containing PEGylated liposomes in a murine solid tumor model. J Control Release 2009; 134: 194-200.
17. Shirasaka T, Nakano K, Takechi T et al. Antitumor activity of 1-M-tegafur-0.4 M 5-chloro-2, 4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996; 56: 2602-6.
18. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998; 34: 1715-20.
19. Sakuramoto S, Sasako M, Yamaguchi T et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-20.
20. Bartlett GR. Colorimetric assay methods for free and phosphorylated glyceric acids. J Biol Chem 1959; 234: 469-71.
21. Cabral H, Nishiyama N, Kataoka K. Optimization of (1, 2-diamino-cyclohexane)platinum (II)- loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity. J Control Release 2007; 121: 146-55.
22. Harashima H, Yamane C, Kume Y, Kiwada H. Kinetic analysis of AUC-dependent saturable clearance of liposomes: mathematical description of AUC dependency. J Pharmacokinet Biopharm 1993; 21: 299-08.
23. Yamada Y, Tahara M, Miya T et al. Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer. Br J Cancer 2008; 98: 1034-8.
24. Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 2003; 30: 5-13.
25. Pietrangeli A, Leandri M, Terzoli E, Jandolo B, Garufi C. Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol 2006; 56: 13-6.
26. Lu D, Wientjes MG, Lu Z, Au JL. Tumor priming enhances delivery and efficacy of nanomedicines. J Pharmacol Exp Ther 2007; 322: 80-8.
27. Ooyama A, Oka T, Zhao HY, Yamamoto M, Akiyama S, Fukushima M. Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts. Cancer Lett 2008; 267: 26-36.
28. Nagano S, Perentes JY, Jain RK, Boucher Y. Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors. Cancer Res 2008; 68: 3795-802.
29. Daemen T, Regts J, Meesters M, Ten Kate MT, Bakker-Woudenberg IA, Scherphof GL. Toxicity of doxorubicin entrapped within long-circulating liposomes. J Control Release 1997; 44: 1-9.
30. Phillips NC. Kupffer cells and liver metastasis. Optimization and limitation of activation of tumoricidal activity. Cancer Metastasis Rev 1989; 8: 231-52.
31. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006; 11: 812-8.